Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.33 |
| ▸ | GHSR | Q92847 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317300 | 1.00 | KCNH2 (0.37) | KCNH2CCR2CYP2D6GHSRROCK2 | |
| SCHEMBL3316369 | 1.00 | KCNH2 (0.37) | KCNH2CCR2CYP2D6GHSRROCK2 | |
| SCHEMBL1484874 | 0.89 | LMNA (0.36) | — | |
| SCHEMBL552030 | 0.89 | LMNA (0.36) | — | |
| SCHEMBL27323802 | 0.85 | KCNH2 (0.37) | KCNH2CCR2CYP2D6GHSRKAT2B | |
| SCHEMBL17827393 | 0.85 | KCNH2 (0.37) | KCNH2CCR2CYP2D6GHSRKAT2B | |
| SCHEMBL26949296 | 0.85 | KCNH2 (0.37) | KCNH2CCR2CYP2D6GHSRKAT2B | |
| SCHEMBL24535944 | 0.82 | KCNH2 (0.38) | KCNH2CCR2CYP2D6GHSRKAT2B | |
| SCHEMBL13755999 | 0.80 | — | — | |
| SCHEMBL3316370 | 0.80 | ADH1B (0.50) | KCNH2CCR2CYP2D6GHSRKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2041141-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006883-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | KCNH2 3671/4885CCR2 3381/4885CYP2D6 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.